Call us : USA : 1-631-381-2994; Europe : 44-207-097-1828
Mail us : info@creative-biolabs.com
Creative Biolabs Bispecific Antibody Blog

Menu

Skip to content
  • Bispecific Antibody Research
  • Bispecific Antibody Clinic
  • News

Monthly Archives: April 2019

Recent Advances in Hot Areas of Bispecific Antibodies Such as PARP Inhibitors

April 17, 2019Bispecific Antibody ResearchBispecific Antibody, PARPbiobsab

In 2018, Loxo Oncology’s “unlimited cancer” targeted therapy Vitrakvi was approved by the U.S. Food and Drug Administration (FDA), becoming the first targeted therapy for patients with neurotrophic receptor tyrosine kinase (NTRK)Read More…

Categories

  • Bispecific Antibody Clinic
  • Bispecific Antibody Research
  • News

Recent Posts

  • Bispecific Antibodies Targeting Dual Tumor-associated Antigens
  • Difficulties and Prospects in the Research and Development of Bispecific Antibodies
  • Current Status of Research and Development of Multispecific Antibodies
  • How to Develop A Qualified Bispecific Antibody
  • Amgen Bispecific Antibody BLINCYTO® (blinatumomab) Significantly Prolongs the Overall Survival Time of Patients with Leukemia

Archives

  • December 2020
  • October 2020
  • August 2020
  • June 2019
  • April 2019
  • March 2019
  • February 2019
  • December 2018
  • November 2018
  • October 2018

Contact Us

USA:
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: info@creative-biolabs.com
Europe:
Tel: 44-207-097-1828
Copyright © Creative Biolabs Bispecific Antibody Blog
Powered by WordPress , Designed and Developed by templatesnext
MENU
  • Bispecific Antibody Research
  • Bispecific Antibody Clinic
  • News